All Clinical Trials in Canada

A listing of 3904 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

Canada

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

NCT06500702

Recruiting

This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD). The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, SAR442970, or rilzabrutinib compared with placebo in participants with primary FSGS or primary MCD aged 16 to 75 years. Study details for each participant include: The study duration... Read More

Gender:

ALL

Ages:

Between 16 years and 75 years

Trial Updated:

08/12/2025

Locations: Investigational Site Number: 8400007, Birmingham, Alabama +57 locations

Investigational Site Number: 8400007, Birmingham, Alabama

Investigational Site Number : 8400015, Orange, California

Investigational Site Number : 8400012, San Francisco, California

Investigational Site Number : 8400014, Chicago, Illinois

Investigational Site Number : 8400017, Hinsdale, Illinois

Investigational Site Number : 8400010, Ann Arbor, Michigan

Investigational Site Number : 8400019, Edina, Minnesota

Investigational Site Number : 8400018, Las Vegas, Nevada

Investigational Site Number : 8400001, New York, New York

Investigational Site Number : 8400021, Chapel Hill, North Carolina

Investigational Site Number : 8400005, El Paso, Texas

Investigational Site Number: 8400016, Houston, Texas

Investigational Site Number : 0320002, Cordoba, Córdoba

Investigational Site Number : 0320001, Buenos Aires, Not set

Investigational Site Number : 0360003, Canberra, Australian Capital Territory

Investigational Site Number : 0360001, Parkville, Victoria

Investigational Site Number : 0760002, Sao Paulo, São Paulo

Investigational Site Number: 0760001, São Paulo, Not set

Investigational Site Number : 1240002, London, Ontario

Investigational Site Number : 1240001, Montreal, Quebec

Investigational Site Number : 1240006, Quebec City, Quebec

Investigational Site Number : 1520002, Santiago, Reg Metropolitana De Santiago

Investigational Site Number : 1520003, Temuco, Not set

Investigational Site Number : 1560001, Beijing, Not set

Investigational Site Number : 1560003, Chengdu, Not set

Investigational Site Number : 1560004, Shanghai, Not set

Investigational Site Number : 2030002, Olomouc, Not set

Investigational Site Number : 2030001, Prague, Not set

Investigational Site Number : 2500002, Créteil, Not set

Investigational Site Number : 2500001, Paris, Not set

Investigational Site Number : 2760002, Berlin, Not set

Investigational Site Number : 2760003, Hannover, Not set

Investigational Site Number : 3000002, Athens, Not set

Investigational Site Number : 3000001, Heraklion, Not set

Investigational Site Number : 3480001, Budapest, Not set

Investigational Site Number : 3800002, Florence, Firenze

Investigational Site Number : 3800003, Naples, Napoli

Investigational Site Number : 3800001, Brescia, Not set

Investigational Site Number : 4840001, Mexico City, Ciudad De Mexico

Investigational Site Number : 4840003, Monterrey, Nuevo León

Investigational Site Number : 5280001, Amsterdam, Not set

Investigational Site Number : 6160002, Opole, Not set

Investigational Site Number : 6200001, Matosinhos, Not set

Investigational Site Number : 6200002, Porto, Not set

Investigational Site Number : 7030003, Banská Bystrica, Not set

Investigational Site Number : 7030001, Martin, Not set

Investigational Site Number : 7240001, Barcelona, Barcelona [Barcelona]

Investigational Site Number : 7240004, Barcelona, Catalunya [Cataluña]

Investigational Site Number : 7240005, Seville, Sevilla

Investigational Site Number : 7240002, Córdoba, Not set

Investigational Site Number : 7240003, Valencia, Not set

Investigational Site Number : 1580001, Taichung, Not set

Investigational Site Number : 1580002, Taipei City, Not set

Investigational Site Number : 7920001, Izmit, Not set

Investigational Site Number : 7920002, Kayseri, Not set

Investigational Site Number : 8260001, Leicester, Leicestershire

Investigational Site Number : 8260004, Salford, Manchester

Investigational Site Number : 8260005, Oxford, Oxfordshire

Conditions: Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion

Learn More ›

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

NCT04862663

Recruiting

A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)

Gender:

ALL

Ages:

Between 18 years and 99 years

Trial Updated:

08/12/2025

Locations: Research Site, Tucson, Arizona +279 locations

Research Site, Tucson, Arizona

Research Site, Fountain Valley, California

Research Site, Glendale, California

Research Site, Los Angeles, California

Research Site, Napa, California

Research Site, Newport Beach, California

Research Site, San Francisco, California

Research Site, Santa Barbara, California

Research Site, Santa Rosa, California

Research Site, Aurora, Colorado

Research Site, New Haven, Connecticut

Research Site, Newark, Delaware

Research Site, Quincy, Illinois

Research Site, Fort Wayne, Indiana

Research Site, Louisville, Kentucky

Research Site, Baton Rouge, Louisiana

Research Site, Covington, Louisiana

Research Site, Annapolis, Maryland

Research Site, Baltimore, Maryland

Research Site, Boston, Massachusetts

Research Site, Detroit, Michigan

Research Site, Grand Rapids, Michigan

Research Site, Hannibal, Missouri

Research Site, Saint Louis, Missouri

Research Site, Omaha, Nebraska

Research Site, Camden, New Jersey

Research Site, Brooklyn, New York

Research Site, Mineola, New York

Research Site, New York, New York

Research Site, Durham, North Carolina

Research Site, Gresham, Oregon

Research Site, Philadelphia, Pennsylvania

Research Site, Pittsburgh, Pennsylvania

Research Site, York, Pennsylvania

Research Site, Providence, Rhode Island

Research Site, Greenville, South Carolina

Research Site, Chattanooga, Tennessee

Research Site, Nashville, Tennessee

Research Site, Dallas, Texas

Research Site, Fort Worth, Texas

Research Site, Houston, Texas

Research Site, San Antonio, Texas

Research Site, Falls Church, Virginia

Research Site, Leesburg, Virginia

Research Site, Midlothian, Virginia

Research Site, Norfolk, Virginia

Research Site, Tacoma, Washington

Research Site, Buenos Aires, Not set

Research Site, Caba, Not set

Research Site, Chivilcoy, Not set

Research Site, Rosario, Not set

Research Site, Santa Fe, Not set

Research Site, Darlinghurst, Not set

Research Site, Miranda, Not set

Research Site, Nedlands, Not set

Research Site, Wahroonga, Not set

Research Site, Waratah, Not set

Research Site, Brasschaat, Not set

Research Site, Brussel, Not set

Research Site, Edegem, Not set

Research Site, Haine-Saint-Paul, Not set

Research Site, Leuven, Not set

Research Site, Alfenas, Not set

Research Site, Blumenau, Not set

Research Site, Natal, Not set

Research Site, Porto Alegre, Not set

Research Site, Porto Velho, Not set

Research Site, São Paulo, Not set

Research Site, Taubaté, Not set

Research Site, Teresina, Not set

Research Site, Vitoria, Not set

Research Site, Abbotsford, British Columbia

Research Site, Kelowna, British Columbia

Research Site, Winnipeg, Manitoba

Research Site, Moncton, New Brunswick

Research Site, Halifax, Nova Scotia

Research Site, Brampton, Ontario

Research Site, Ottawa, Ontario

Research Site, Sault Ste. Marie, Ontario

Research Site, Toronto, Ontario

Research Site, Sherbrooke, Quebec

Research Site, Chicoutimi, Not set

Research Site, Montreal, Not set

Research Site, Beijing, Not set

Research Site, Bengbu, Not set

Research Site, Changchun, Not set

Research Site, Changsha, Not set

Research Site, Chengdu, Not set

Research Site, Chongqing, Not set

Research Site, Guangzhou, Not set

Research Site, Hangzhou, Not set

Research Site, Hefei, Not set

Research Site, Jinan, Not set

Research Site, Nanchang, Not set

Research Site, Nanjing, Not set

Research Site, Nanning, Not set

Research Site, Shandong, Not set

Research Site, Shanghai, Not set

Research Site, Shenyang, Not set

Research Site, Urumqi, Not set

Research Site, Wuhan, Not set

Research Site, Xi'an, Not set

Research Site, Xiangyang City, Not set

Research Site, Xian, Not set

Research Site, Xuzhou, Not set

Research Site, Zhengzhou, Not set

Research Site, Aalborg, Not set

Research Site, Aarhus N, Not set

Research Site, Hillerød, Not set

Research Site, Odense, Not set

Research Site, Bobigny, Not set

Research Site, Clermont Ferrand, Not set

Research Site, Limoges, Not set

Research Site, Lyon, Not set

Research Site, Plerin, Not set

Research Site, Rouen, Not set

Research Site, St Herblain, Not set

Research Site, Villejuif, Not set

Research Site, Augsburg, Not set

Research Site, Berlin, Not set

Research Site, Bottrop, Not set

Research Site, Dresden, Not set

Research Site, Erlangen, Not set

Research Site, Frankfurt am Main, Not set

Research Site, Freiburg, Not set

Research Site, Georgsmarienhütte, Not set

Research Site, Hamburg, Not set

Research Site, Hannover, Not set

Research Site, Heilbronn, Not set

Research Site, Kiel, Not set

Research Site, Leipzig, Not set

Research Site, Mannheim, Not set

Research Site, Mönchengladbach, Not set

Research Site, Münster, Not set

Research Site, Regensburg, Not set

Research Site, Stade, Not set

Research Site, Trier, Not set

Research Site, Ulm, Not set

Research Site, Bangalore, Not set

Research Site, Jaipur, Not set

Research Site, JAipur, Not set

Research Site, Mohali, Not set

Research Site, Mysuru, Not set

Research Site, Nagpur, Not set

Research Site, New Delhi, Not set

Research Site, Pondicherry, Not set

Research Site, Vadodara, Not set

Research Site, Varanasi, Not set

Research Site, Aviano, Not set

Research Site, Bologna, Not set

Research Site, Catanzaro, Not set

Research Site, Firenze, Not set

Research Site, Milano, Not set

Research Site, Milan, Not set

Research Site, Misterbianco, Not set

Research Site, Napoli, Not set

Research Site, Padova, Not set

Research Site, Prato, Not set

Research Site, Reggio Emilia, Not set

Research Site, Roma, Not set

Research Site, Rozzano, Not set

Research Site, Chiba-shi, Not set

Research Site, Chuo-ku, Not set

Research Site, Hidaka-shi, Not set

Research Site, Hirakata-shi, Not set

Research Site, Hiroshima-shi, Not set

Research Site, Isehara-shi, Not set

Research Site, Kagoshima-shi, Not set

Research Site, Koto-ku, Not set

Research Site, Kyoto-shi, Not set

Research Site, Matsuyama-shi, Not set

Research Site, Nagoya-shi, Not set

Research Site, Naha-shi, Not set

Research Site, Okayama-shi, Not set

Research Site, Osaka-shi, Not set

Research Site, Ota-shi, Not set

Research Site, Sapporo-shi, Not set

Research Site, Sendai-shi, Not set

Research Site, Shimotsuke-shi, Not set

Research Site, Shinagawa-ku, Not set

Research Site, Shinjuku-ku, Not set

Research Site, Suita-shi, Not set

Research Site, Takasaki-shi, Not set

Research Site, Tsu-shi, Not set

Research Site, Yokohama-shi, Not set

Research Site, Goyang-si, Not set

Research Site, Seoul, Not set

Research Site, George Town, Not set

Research Site, Kuala Lumpur, Not set

Research Site, Kuching, Not set

Research Site, Pulau Pinang, Not set

Research Site, Selangor, Not set

Research Site, Bialystok, Not set

Research Site, Bydgoszcz, Not set

Research Site, Gdańsk, Not set

Research Site, Koszalin, Not set

Research Site, Kraków, Not set

Research Site, Lodz, Not set

Research Site, Lublin, Not set

Research Site, Rzeszów, Not set

Research Site, Warszawa, Not set

Research Site, Łódź, Not set

Research Site, Barcelona, Not set

Research Site, Granada, Not set

Research Site, Lérida, Not set

Research Site, Madrid, Not set

Research Site, Málaga, Not set

Research Site, Pamplona, Not set

Research Site, Santiago de Compostela, Not set

Research Site, Lund, Not set

Research Site, Solna, Not set

Research Site, Växjö, Not set

Research Site, Kaohsiung, Not set

Research Site, Taichung, Not set

Research Site, Tainan, Not set

Research Site, Taipei, Not set

Research Site, Taoyuan, Not set

Research Site, Bangkok, Not set

Research Site, Chiang Mai, Not set

Research Site, Dusit, Not set

Research Site, Hat Yai, Not set

Research Site, Khon Kaen, Not set

Research Site, Lampang, Not set

Research Site, Ratchathewi, Not set

Research Site, Ankara, Not set

Research Site, Antalya, Not set

Research Site, Goztepe Istanbul, Not set

Research Site, Karsiyaka, Not set

Research Site, Kayseri, Not set

Research Site, Malatya, Not set

Research Site, Samsun, Not set

Research Site, Derry, Not set

Research Site, Guildford, Not set

Research Site, London, Not set

Research Site, Taunton, Not set

Research Site, York, Not set

Research Site, Can Tho, Not set

Research Site, Hanoi, Not set

Research Site, Ho Chi Minh city, Not set

Research Site, Ho Chi Minh, Not set

Research Site, Hồ Chí Minh, Not set

Research Site, Vinh, Not set

Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer

Learn More ›

Using Cannabis to Treat Restless Legs Syndrome

NCT06863740

Recruiting

Restless Legs Syndrome (RLS) is a disorder that causes painful and uncomfortable sensations in the legs, and its symptoms have a significant impact on sleep and quality of life. Cannabis has been used by some RLS patients as a treatment due to its painkilling and drowsiness effects, however there has never been a clinical research trial investigating cannabis in patients with RLS. A controlled trial is needed to establish how safe and feasible cannabis is as a treatment for RLS. The investigator... Read More

Gender:

ALL

Ages:

25 years and above

Trial Updated:

08/12/2025

Locations: Sunnybrook Health Sciences Centre, Toronto, Ontario +1 locations

Conditions: Restless Leg Syndrome (RLS)

Learn More ›

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

NCT06428396

Recruiting

The purpose of this study is to assess the efficacy and safety of belzutifan (MK-6482) plus fulvestrant compared to everolimus plus endocrine therapy (ET) (investigator's choice of fulvestrant or exemestane) in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) unresectable metastatic breast cancer. There is no formal hypothesis testing in this study.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/12/2025

Locations: City of Hope - Phoenix ( Site 0006), Goodyear, Arizona +36 locations

City of Hope - Phoenix ( Site 0006), Goodyear, Arizona

Cedars Sinai Medical Center ( Site 0012), Beverly Hills, California

Moores Cancer Center at UC San Diego Health ( Site 0025), La Jolla, California

USC/Norris Comprehensive Cancer Center ( Site 0013), Los Angeles, California

USC Norris Oncology Hematology Newport Beach ( Site 0029), Newport Beach, California

Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0011), Marietta, Georgia

Southeastern Regional Medical Center ( Site 0010), Newnan, Georgia

CHRISTUS Highland ( Site 0005), Shreveport, Louisiana

Renown Regional Medical Center ( Site 0018), Reno, Nevada

MD Anderson ( Site 0015), Houston, Texas

Mays Cancer Center ( Site 0022), San Antonio, Texas

Centro de Investigaciones Metabólicas (CINME)-Oncology ( Site 0504), Caba, Buenos Aires

Hospital Británico de Buenos Aires-Oncology ( Site 0500), Ciudad autónoma de Buenos Aires, Buenos Aires

Instituto de Investigaciones Clínicas Mar del Plata ( Site 0502), Mar del Plata, Buenos Aires

Instituto Alexander Fleming-Alexander Fleming ( Site 0505), Ciudad Autónoma de Buenos Aires, Caba

Sanatorio Allende - Cerro-Oncology ( Site 0506), Córdoba, Cordoba

Instituto de Oncología de Rosario ( Site 0501), Rosario, Santa Fe

Jewish General Hospital ( Site 0400), Montreal, Quebec

Centro de Investigación del Maule ( Site 4106), Talca, Maule

Bradfordhill ( Site 4100), Santiago., Region M. De Santiago

FALP ( Site 4102), Santiago, Region M. De Santiago

Pontificia Universidad Catolica de Chile ( Site 4108), Santiago, Region M. De Santiago

IMAT S.A.S ( Site 1205), Monteria, Cordoba

Oncologos Del Occidente ( Site 1200), Pereira, Risaralda

Fundacion Valle del Lili ( Site 1204), Cali, Valle Del Cauca

Seoul National University Hospital ( Site 3100), Seoul, Not set

Samsung Medical Center ( Site 3101), Seoul, Not set

National Cheng Kung University Hospital ( Site 3300), Tainan, Not set

National Taiwan University Hospital ( Site 3301), Taipei, Not set

National Taiwan University Cancer Center ( Site 3302), Taipei, Not set

Faculty of Medicine - Khon Kaen University ( Site 3502), Muang, Khon Kaen

Faculty of Medicine Siriraj Hospital ( Site 3500), Bangkoknoi, Krung Thep Maha Nakhon

Songklanagarind Hospital ( Site 3501), Hat Yai, Songkhla

The Royal Cornwall Hospital ( Site 1904), Truro, England

St Bartholomews Hospital ( Site 1900), London, London, City Of

The Christie Hospital NHS Foundation Trust ( Site 1902), Withington, Manchester

Ipswich Hospital ( Site 1911), Ipswich, Suffolk

Conditions: Metastatic Breast Cancer

Learn More ›

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

NCT05070845

Recruiting

This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (\>3 months and ≤12 months), or chronic (\>12 months) ITP

Gender:

ALL

Ages:

Between 18 years and 70 years

Trial Updated:

08/12/2025

Locations: East Carolina University, Greenville, North Carolina +27 locations

East Carolina University, Greenville, North Carolina

Clinical Research Unit Haematology, Division of Cancer Services, St. George Hospital, Kogarah, New South Wales

Liverpool Hospital, Liverpool, New South Wales

South West Radiology, Liverpool, New South Wales

Slade Pharmacy, Mount Kuring-Gai, New South Wales

Calvary Mater Newcastle, Waratah, New South Wales

Flinders Medical Centre, Bedford Park, South Australia

ICON Cancer Centre - Kurralta Park, Kurralta Park, South Australia

The Alfred Hospital, Melbourne, Victoria

Royal Perth Hospital, Perth, Western Australia

Unity Health Toronto, St. Michael's Hospital, Toronto, Ontario

McGill University Health Centre, Montreal, Quebec

Fakultni nemocnice Hradec Kralove, Hradec Kralove, Not set

Vseobecna fakultni nemocnice v Praze, Praha 2, Not set

Pécsi Tudományegyetem Klinikai Központ, Pécs, Baranya

Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvár, Somogy

Semmelweis University, Budapest, Not set

Petz Aladár Egyetemi Oktató Kórház, Györ, Not set

AIDPORT Sp. z o.o., Skórzewo, Wielkopolskie

InterHem, Bialystok, Not set

Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne, Gdansk, Not set

Pratia Onkologia Katowice, Katowice, Not set

Uniwersytecki Szpital Kliniczny w Poznaniu, Poznan, Not set

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Wroclaw, Not set

Addenbrooke's Hospital, Cambridge, Cambridgeshire

Derriford Hospital, Plymouth, Devon

The Royal Cornwall Hospital, Truro, England

Hammersmith Hospital, London, Not set

Conditions: Primary Immune Thrombocytopenia

Learn More ›

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075

Recruiting

This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated tumors, advanced wt (wild-type) gastrointestinal stromal tumor (wt GIST), or advanced solid tumors with hypoxia inducible factor-2 alpha (HIF-2α) related genetic alterations. The primary objective of the study is to evaluate the objective response rate (ORR) of belzutif... Read More

Gender:

ALL

Ages:

12 years and above

Trial Updated:

08/12/2025

Locations: Cedars-Sinai Medical Center ( Site 0110), Los Angeles, California +81 locations

Cedars-Sinai Medical Center ( Site 0110), Los Angeles, California

Northwestern University - Robert H. Lurie Comprehensive Cancer Center ( Site 0130), Chicago, Illinois

University of Iowa ( Site 0104), Iowa City, Iowa

Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site 0108), Baltimore, Maryland

National Institutes of Health ( Site 0125), Bethesda, Maryland

Massachusetts General Hospital ( Site 0111), Boston, Massachusetts

University of Michigan ( Site 0126), Ann Arbor, Michigan

Washington University-Internal Medicine/Oncology ( Site 0124), Saint Louis, Missouri

Icahn School of Medicine at Mount Sinai ( Site 0123), New York, New York

Penn Medicine: University of Pennsylvania Health System-Heme/Onc ( Site 0127), Philadelphia, Pennsylvania

SCRI Oncology Partners ( Site 7000), Nashville, Tennessee

Vanderbilt University Medical Center ( Site 0107), Nashville, Tennessee

University of Texas MD Anderson Cancer Center ( Site 0112), Houston, Texas

Prince of Wales Hospital-Medical Oncology ( Site 1601), Randwick, New South Wales

The Royal Melbourne Hospital ( Site 1602), Parkville, Victoria

Arthur J.E. Child Comprehensive Cancer Centre ( Site 0203), Calgary, Alberta

Princess Margaret Cancer Centre ( Site 0202), Toronto, Ontario

FALP ( Site 2200), Santiago, Region M. De Santiago

Centro de Oncología de Precisión ( Site 2203), Santiago, Region M. De Santiago

Peking University First Hospital-Urology ( Site 1900), Beijing, Beijing

Sun Yat-sen University Cancer Center ( Site 1905), Guangzhou, Guangdong

Renji Hospital Shanghai Jiao Tong University School of Medicine ( Site 1904), Shanghai, Shanghai

West China Hospital of Sichuan University ( Site 1906), Cheng Du, Sichuan

Rigshospitalet ( Site 0304), Copenhagen, Hovedstaden

Rigshospitalet-Department of Endocrinology ( Site 0303), Copenhagen, Hovedstaden

Odense Universitetshospital ( Site 0302), Odense C, Syddanmark

CHU Strasbourg-Hautepierre-Medecine Interne, Endocrinologie et Nutrition ( Site 0402), Strasbourg, Alsace

Institut Paoli-Calmettes-Oncology ( Site 0406), Marseille, Bouches-du-Rhone

Gustave Roussy ( Site 0403), Villejuif, Ile-de-France

Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre ( Site 0407), Le Kremlin-Bicêtre, Paris

Hôpital Edouard Herriot-oncologie ( Site 0405), Lyon, Rhone-Alpes

Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 0404), Paris, Not set

Klinikum der Ludwig-Maximilians-Universitaet Muenchen-Department of Internal Medicine IV, Division ( Site 0501), München, Bayern

Comprehensive Cancer Center Mainfranken-Div. of Endocrinology and Diabetes ( Site 0500), Würzburg, Bayern

Universitaetsklinikum Freiburg ( Site 0504), Freiburg, Brandenburg

Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 0505), Düsseldorf, Nordrhein-Westfalen

Charité Universitaetsmedizin Berlin - Campus Mitte-Department of Endocrinology and Metabolism ( Site 0503), Berlin, Not set

Semmelweis University-Belgyógyászati és Onkológiai Klinika Hematológia Osztály ( Site 0600), Budapest, Not set

Sheba Medical Center-Institute of Endocrinology, Diabetes and Metabolism ( Site 1400), Ramat Gan, Not set

Sourasky Medical Center ( Site 1401), Tel Aviv, Not set

University of Naples Federico II-Dipartimento di Medicina Clinica e Chirurgia ( Site 0704), Naples, Campania

Fondazione IRCCS Istituto Nazionale dei Tumori-S.C. Oncologia Medica 2- Sarcomi ( Site 0709), Milan, Lombardia

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 0708), Bologna, Not set

Azienda Ospedaliera Spedali Civili di Brescia-Oncology ( Site 0701), Brescia, Not set

Ospedale San Raffaele-Oncologia Medica ( Site 0705), Milano, Not set

Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Medica Gastrointestinale e Tumori Neuroe ( Site 0700), Milano, Not set

Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma ( Site 0703), Verona, Not set

Hokkaido University Hospital ( Site 1800), Sapporo, Hokkaido

Yokohama City University Hospital ( Site 1804), Yokohama-shi, Kanagawa

Kochi Medical School Hospital ( Site 1807), Nankoku, Kochi

National Cancer Center Hospital ( Site 1802), Chuo-ku, Tokyo

Kyoto University Hospital ( Site 1806), Kyoto, Not set

Tokyo Women's Medical University Adachi Medical Center ( Site 1803), Tokyo, Not set

Seoul National University Hospital ( Site 2001), Jongno-gu, Seoul

Asan Medical Center ( Site 2000), Songpa-gu, Seoul

Universitair Medisch Centrum Utrecht ( Site 1530), Utrecht, Not set

Oslo Universitetssykehus Radiumhospitalet ( Site 2400), Oslo, Not set

START Lisbon - Hospital de Santa Maria ( Site 2601), Lisbon, Lisboa

Instituto Portugues de Oncologia Do Porto Francisco Gentil E.P.E. ( Site 2600), Porto, Not set

GBUZ Republican Clinical Oncological Dispensary ( Site 0804), Ufa, Baskortostan, Respublika

Saint Petersburg State University-Clinic of advanced medical technologies n. a. Nicolay I. Pirogov ( Site 0805), Saint Petersburg, Leningradskaya Oblast

Saint-Petersburg City Clinical Oncology Dispensary-Department of chemotherapy ( Site 0803), Saint Petersburg, Leningradskaya Oblast

Fed State Budgetary Inst N.N. Blokhin Med Center of Oncology MHRF ( Site 0801), Moscow, Moskva

Endocrinology Research Center of Rosmedtechnologies-Surgery ( Site 0809), Moscow, Moskva

National Cancer Centre Singapore ( Site 1700), Singapore, Central Singapore

Hospital Universitario Central de Asturias-Medical Oncology ( Site 1101), Oviedo, Asturias

MD Anderson Cancer Center-Oncology ( Site 1102), Madrid, Madrid, Comunidad De

Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1103), Madrid, Madrid, Comunidad De

Hospital Universitari Vall d'Hebron ( Site 1100), Barcelona, Not set

Skanes University Hospital Lund ( Site 1200), Lund, Skane Lan

Karolinska Universitetssjukhuset Solna ( Site 1202), Stockholm, Stockholms Lan

Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 1201), Uppsala, Uppsala Lan

Sahlgrenska Universitetssjukhuset-Department of Oncology CTU Clinical Trial Unit ( Site 1204), Gothenburg, Vastra Gotalands Lan

Baskent University Adana Training Hospital ( Site 0906), Yuregir, Adana

Ege University Medicine of Faculty ( Site 0900), Bornova, Izmir

Hacettepe Universitesi-oncology hospital ( Site 0901), Ankara, Not set

Ankara Bilkent Şehir Hastanesi. ( Site 0904), Ankara, Not set

Istanbul Universitesi Cerrahpasa-Medical Oncology ( Site 0902), Istanbul, Not set

Addenbrooke's Hospital ( Site 1309), Cambridge, Cambridgeshire

Royal Free Hospital ( Site 1302), London, England

The Beatson West of Scotland Cancer Centre ( Site 1308), Glasgow, Glasgow City

Hammersmith Hospital-Medical Oncology ( Site 1304), London, London, City Of

Conditions: Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers

Learn More ›

Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

NCT06667414

Recruiting

For participation in this epidemiological study, a single-day visit at the study site is required. Participants will be recruited from Huntington Disease clinics, and they will be asked to answer questions regarding their demographics, including sex, age, race and ethnicity, and their medical and medication history. At the end of the visit, a blood sample will be drawn to allow testing with a sequencing assay that is specifically designed for phasing single nucleotide polymorphisms (SNPs) on the... Read More

Gender:

ALL

Ages:

Between 25 years and 60 years

Trial Updated:

08/12/2025

Locations: Uab Medicine, Birmingham, Alabama +40 locations

Uab Medicine, Birmingham, Alabama

Barrow Neurological Institute, Phoenix, Arizona

University of California San Diego, La Jolla, California

University of California Davis Medical System, Sacramento, California

CenExel Rocky Mountain Clinical Research, LLC, Englewood, Colorado

University of South Florida, Tampa, Florida

Northwestern University, Chicago, Illinois

University of Iowa Hospitals and Clinics, Iowa City, Iowa

John Hopkins University School of Medicine, Baltimore, Maryland

Beth Israel Deaconess Medical Center, Boston, Massachusetts

University of Pittsburgh, Pittsburgh, Pennsylvania

EvergreenHealth Investigational Drug Services, Kirkland, Washington

Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires, Not set

Calvary Health Care Bethlehem, Caulfield South, New South Wales

Westmead Hospital, Westmead, New South Wales

Royal Melbourne Hospital, Parkville, Victoria

University of Alberta, Edmonton, Alberta

University of British Columbia Hospital, Vancouver, British Columbia

Centricity Research, Halifax, Nova Scotia

North York General Hospital, Toronto, Ontario

McGill University, Montreal, Quebec

Charité - Universitätsmed. Berlin, Klinik für Psychiatrie und Psychotherapie, Berlin, Not set

St. Josef-Hospital, Neurologische Klinik der Ruhr-Uni, Bochum, Not set

Universitätsklinikum Erlangen, Abteilung Molekulare Neurologie, Erlangen, Not set

Universitätsklinikum Ulm, Ulm, Not set

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Lombardia

Auckland DHB - Neurlogy Department, Auckland, Not set

New Zealand Brain Research Institute, Christchurch, Not set

Wellington Hospital, Wellington, Not set

Szpital Sw. Wojciecha, Gda?sk, Not set

Wojskowy Instytut Medycyny Lotniczej, Warszawa, Not set

Unidade Local de Saude de Santa Maria, E.P.E. - Hospital de Santa Maria, Lisboa, Not set

CNS - Campus Neurológico, Torres Vedras, Not set

Hospital Universitario de Badajoz, Badajoz, Not set

Hospital de la Santa Creu i Sant Pau, Barcelona, Not set

Hospital Universitario de Burgos. Servicio de Neurología, Burgos, Not set

Hospital Ramon y Cajal, Madrid, Not set

Birmingham and Solihull Mental Health Foundation NHS Trust, Birmingham, Not set

Addenbrookes Hospital, Cambridge, Not set

National Hospital For Neurology and Neurosurgery, London, Not set

John Radcliffe Hospital, Oxford, Not set

Conditions: Huntington Disease

Learn More ›

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

NCT03363373

Recruiting

Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose. Naxitamab, also known as hu3F8 is a humanised monoclonal antibody targeting GD2

Gender:

ALL

Ages:

1 year and above

Trial Updated:

08/12/2025

Locations: University of Florida, Gainesville, Florida +25 locations

University of Florida, Gainesville, Florida

University of Chicago, Chicago, Illinois

Riley Hospital for Children, Indianapolis, Indiana

Memorial Sloan Kettering Cancer Center, New York, New York

Nationwide Children's Hospital, Columbus, Ohio

M.D. Anderson Cancer Center, Houston, Texas

The Hospital for Sick Children, Toronto, Not set

Rigshospitalet, København, Not set

Hopital pour enfants de la Timone, Marseille, Not set

University Medical Center Hamburg-Eppendorf, Hamburg, Not set

Johannes Gutenberg-Universität, Mainz, Not set

University Hospital Regensburg, Regensburg, Not set

Hong Kong Children's Hospital, Hong Kong, Not set

Queen Mary Hospital, Hong Kong, Not set

Tata Memorial Centre, Mumbai, Not set

Giannina Gaslini Hospital, Genoa, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Not set

Ospedale Pediatrico Bambino Gesù, Rome, Not set

Hospital Sant Joan de Déu, Barcelona, Not set

Hospital Infantil Universitario Niño Jesús, Madrid, Not set

Hospital Universitario Virgen Del Rocío, Sevilla, Not set

Hospital Universitario y Politécnico La Fe, Valencia, Not set

The Royal Glasgow Children's Hospital, Glasgow, Not set

Leeds General Infirmary, Leeds, Not set

The Royal Marsden, London, Not set

University Hospital Southampton, Southampton, Not set

Conditions: Neuroblastoma

Learn More ›

Identifying the Limits of Survivability in Heat-exposed Older Females

NCT07032493

Recruiting

Climate change increases extreme heat events, elevating global heat-illness risk. Females have reduced heat loss capacity (\~5%) compared to males, driven by differences in skin blood flow and sweating responses. While findings on sex-mediated mortality are mixed, some studies suggest older females (≥65 years), face higher heat-related mortality/morbidity risks, evidenced by disproportionate female deaths in the 2021 Western Heat Dome. The effects of extreme uncompensable heat on older females remain understudied. Heat exposure initially causes net heat gain, raising core/skin temperatures and triggering heat-loss responses. Under compensable heat stress, heat loss balances gain, stabilizing core temperature. Uncompensable heat stress (exceeding maximal dissipation capacity) causes continuous core temperature rise, posing severe health risks. The specific temperature and relative humidity (RH) limits where compensability is lost are critical survival determinants, influenced by age and sex. Ramping protocols identify these limits: participants face progressively increasing heat stress (e.g., staged humidity rises) while core temperature is monitored. Core temperature typically stabilizes initially, then exhibits an abrupt rapid increase at an inflection point, operationally defined as the limit of compensability. Despite increasing use, ramping protocol validity for accurately identifying this threshold remains unverified. This project assesses ramping protocol validity for determining uncompensable conditions in older females and evaluates cumulative thermal and cardiovascular strain, as well as psychological and cognitive responses to both uncompensable and compensable heat. Participants will complete five trials. Trial 1 (Ramping): Rest at 42°C, 28% RH for 70min, then incremental RH increases (3% every 10min) to 70% RH. Individual core temperature (rectal) inflection points are identified from the ramping trial. Trials 2-5 (Fixed Conditions, Randomized): i) \~10% below inflection; ii) \~5% below inflection; iii) \~5% above inflection; iv) Thermo-neutral control (26°C, 45% RH). Comparing the rate of rectal temperature change and cumulative strain during prolonged fixed exposures (especially below vs. above inflection) will validate if the ramping inflection point represents the true limit of compensability for older females. Read Less

Gender:

FEMALE

Ages:

Between 65 years and 85 years

Trial Updated:

08/12/2025

Locations: University of Ottawa, Ottawa, Ontario +1 locations

Conditions: Heat Stress, Temperature Change, Body, Aging, Thermoregulation, Heat Exposure

Learn More ›

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

NCT05512390

Recruiting

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-319 in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL)... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/12/2025

Locations: University of Arizona Cancer Center - Tucson /ID# 247752, Tucson, Arizona +17 locations

Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma

Learn More ›

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

NCT06991257

Recruiting

The purpose of this study is to learn about the safety and effects of the study medicine (PF-07328948) for the possible treatment of heart failure (HF).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/12/2025

Locations: National Heart Institute, Beverly Hills, California +23 locations

National Heart Institute, Beverly Hills, California

Orange County Research Center, Lake Forest, California

FWD Clinical Research, Boca Raton, Florida

Amavita Research Services, North Miami Beach, Florida

Chicago Medical Research, Hazel Crest, Illinois

Velocity Clinical Research, Lincoln, Pioneer Heart Institute, Lincoln, Nebraska

Headlands Horizons, LLC dba Headlands Research-Brownsville, Brownsville, Texas

Valley Regional Medical Center, Brownsville, Texas

North Dallas Research Associates, McKinney, Texas

Northwest Houston Heart Center, Tomball, Texas

Diex Recherche Trois-Rivieres, Trois-Rivieres, Quebec

Kasugai Municipal Hospital, Kasugai, Aichi

Seikeikai New Tokyo Heart Clinic, Matsudo, Chiba

Sagamihara Kyodo Hospital, Sagamihara, Kanagawa

Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa

National Hospital Organization Yokohama Medical Center, Yokohama, Kanagawa

National Hospital Organization Mie Chuo Medical Center, Tsu, MIE

National Hospital Organization Sendai Medical Center, Sendai, Miyagi

National Hospital Organization Saitama Hospital, Wako, Saitama

National Hospital Organization Tokyo Medical Center, Meguro-Ku, Tokyo

Teine Keijinkai Hospital, Sapporo, Tokyo

NewHeart Watanabe Institute, Suginami, Tokyo

Sekino Hospital, Toshimaku, Tokyo

National Hospital Organization Iwakuni Clinical Center, Iwakuni, Yamaguchi

Conditions: Heart Failure

Learn More ›

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

NCT05967689

Recruiting

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/12/2025

Locations: University of Alabama at Birmingham, Birmingham, Alabama +78 locations

University of Alabama at Birmingham, Birmingham, Alabama

City of Hope - Duarte, Duarte, California

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

Memorial Sloan Kettering Cancer Center - Basking Ridge, Basking Ridge, New Jersey

Memorial Sloan Kettering Cancer Center - Monmouth, Middletown, New Jersey

Memorial Sloan Kettering Cancer Center - Bergen, Montvale, New Jersey

Memorial Sloan Kettering Cancer Center - Commack, Commack, New York

Memorial Sloan Kettering Cancer Center - Westchester, Harrison, New York

MSK Cancer Center, Long Island City, New York

Memorial Sloan Kettering Cancer Center - Nassau, Uniondale, New York

Gabrail Cancer and Research Center, Canton, Ohio

Zangmeister Cancer Center, Columbus, Ohio

The Toledo Clinic Cancer Center, Toledo, Ohio

SCRI Oncology Partners, Nashville, Tennessee

University of Texas MD Anderson Cancer Center, Houston, Texas

Virginia Cancer Specilalist, Fairfax, Virginia

IDS Pharmacy, Milwaukee, Wisconsin

Bankstown-Lidcombe Hospital, Bankstown, New South Wales

Genesis Care North Shore, Saint Leonards, New South Wales

Joondalup Hospital Pharmacy, Joondalup, Western Australia

William Osler Health System - Brampton Civic Hospital, Brampton, Not set

Nouvel Hôpital Civil, Strasbourg, Aslace

CHU Caen Normandie, Caen cedex 9, Basse-Normandie

Institut Curie, Paris, Ile-de-France

Centre Hospitalier Universitaire Limoges, Limoges cedex, Limousin

Hopital Haut Leveque, Pessac, Nouvelle-Aquitaine

Hôpital Nord Marseille, Marseille, Provence Alpes Cote d´Azur

Centre Leon Berard, Lyon, Rhone-Alpes

Hopital Nord Laennec, Saint-Herblain, Not set

Hopital Ambroise Pare, Boulogne-Billancourt, Île-de-France

Gesundheit Nordhessen Holding AG, Kassel, Hassen

Uniklinik Dresden, Dresden, Not set

UKGM Studienzentrale, Gießen, Not set

UKR Innere Med II Pneumologie, Regensburg, Not set

Queen Mary Hospital, Pok Fu Lam, Hong Kong Island

Azienda Ospedaliero - Universitaria Careggi, Firenze, Florence

Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Forli-Cesena

Azienda Socio-Sanitaria Territoriale di Cremona, Cremona, Not set

Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele, Milan, Not set

Azienda Ospedaliero-Universitaria di Parma, Parma, Not set

Ospedale S. Maria delle Croci, Ravenna, Not set

Aichi Cancer Center, Nagoya, Aichi

National Cancer Center Hospital East, Kashiwa-shi, Chiba

NHO Kyushu Cancer Center, Fukuoka-shi, Hukuoka

Sendai Kousei Hospital, Sendai, Miyagi

Niigata Cancer Center Hospital, Niigata-shi, Niigata

Kindai University Hospital, Osakasayama, Osaka

Shizuoka Cancer Center, Sunto-gun, Sizuoka

National Cancer Center Hospital, Chuo Ku, Tokyo

Cancer Institute Hospital of JFCR, Koto-ku, Tokyo

Okayama University Hospital, Okayama, Not set

National Cancer Center - Korea, Goyang-si, Gyeonggi-do

Saint Vincent's Hospital, Suwon-si, Gyeonggi-do

Ajou University Hospital, Suwon-si, Gyeonggi-do

Gyeongsang National University Hospital, Jinju, Gyeongsangnamdo [Kyongsangnam-do]

Inha University Hospital, Incheon, Incheon Gwang'yeogsi [Inch'on-Kwangyokshi]

Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do

Seoul National University Hospital, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi]

Asan Medical Center, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi]

Korea University Guro Hospital, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi]

Seoul St. Mary's Hospital, Soeul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi]

Hospital Regional Universitario de Málaga - Hospital General, Málaga, Malaga

UOMi Clinica Mi Tres Torres, Barcelona, Not set

Hospital Quirónsalud Barcelona, Barcelona, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

Complejo Hospitalario de Jaen, Jaén, Not set

MD Anderson Cancer Center Madrid, Madrid, Not set

Hospital Universitario Fundación Jiménez Díaz, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital La Paz, Madrid, Not set

Istinye Üniversite Hastanesi Liv Hospital Bahcesehir, Esenyurt, Istanbul

Medical Park Seyhan Hastanesi, Adana, Not set

Trakya Üniversitesi Saglik Arastirma ve Uygulama Merkezi, Edirne, Not set

Bagcilar Medipol Mega Universite Hastanesi, Istanbul, Not set

Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul, Not set

Royal Free Hospital NHS Foundation Trust, Barnet, England

The Christie NHS Foundation Trust, Manchester, England

Nottingham University Hospitals NHS Trust, Nottingham, England

Conditions: Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

Learn More ›